Outcome raises stakes in confrontation between doctors and pharmaceutical companies fighting to protect high prices A groundbreaking trial funded by the NHS has shown that a cheap, unlicensed drug to prevent blindness is just as effective as the expensive one marketed by a major pharmaceutical company. If all patients needing treatment were given unlicensed Avastin injections instead of Lucentis, the NHS could save £84.5m, the researchers calculate
See more here:
Blindness prevention drug could save NHS £84.5m, trial results show
